Sanofi to test Parkinson's drug with Michael J. Fox Foundation

PARIS Thu Apr 19, 2012 11:27am IST

Related Topics

Stocks

   

PARIS (Reuters) - French drugmaker Sanofi said on Thursday it would collaborate with the Michael J. Fox Foundation to test an early- stage experimental treatment for Parkinson's disease.

Under the terms of the collaboration, MJFF will sponsor a phase I clinical trial to study the safety and tolerability of Sanofi's AVE8112, a drug that has shown promise in preclinical tests as a therapy for some of the psychiatric symptoms of the disease.

Parkinson's disease is a brain disorder that leads to shaking and difficulty with walking as well as mood changes and impaired memory.

All data and results generated by the clinical trial will be owned by MJFF and shared with Sanofi. Further development plans will be based on the results of the study, Sanofi said.

Patient enrollment in the study, which will be conducted in the U.S., is expected to begin later this year.

(Reporting by Elena Berton; Editing by Nina Sovich)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Ebola Outbreak

Diabetes And TB

Diabetes And TB

Experts sound alarm as diabetes fuels cases of TB.  Full Article 

Microsoft Band

Microsoft Band

Microsoft launches wearable fitness device for $199.  Full Article 

Long-Term Effect

Long-Term Effect

Having controlling parents may affect later relationships.  Full Article 

Exercise Trend

Exercise Trend

Paddleboard yoga stands venerable practice on its head, on water.  Full Article 

Spike In Polio Cases

Spike In Polio Cases

'Disastrous' health campaign feeds Pakistan's worrying polio spike.  Full Article 

Factbox On GM Crops

Factbox On GM Crops

GMO crops have history of controversy.  Factbox 

Teal Pumpkin Project

Teal Pumpkin Project

Painted pumpkins raising awareness about food allergies.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage